PIROXIMONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H11N3O2
Molecular Weight	217.2239
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2

InChI

InChIKey=OQGWJZOWLHWFME-UHFFFAOYSA-N

InChI=1S/C11H11N3O2/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7/h3-6H,2H2,1H3,(H2,13,14,16)

HIDE SMILES / InChI

Molecular Formula	C11H11N3O2
Molecular Weight	217.2239
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2065688 | https://adisinsight.springer.com/drugs/800000260 | https://www.ncbi.nlm.nih.gov/pubmed/2419699

Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.	2012-10-17	22981620
Therapeutic benefit of pentostatin in severe IL-10-/- colitis.	2008-07	18340641
A comparison of the inotropic effects of milrinone and piroximone.	2001-01	17851157
Clinical pharmacokinetics of vasodilators. Part II.	1998-07	9673832
Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro.	1997-10-15	9361363
Preischemic bolus application of piroximone studied on the isolated rabbit heart--a second look including biochemical data.	1996	8880129
[Acute hemodynamic effects of piroximone i.v. in patients with severe heart failure].	1995-10	7502570
Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.	1995-05-26	7556414
Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils.	1995-05	7585334
Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency.	1995-02	7742160
Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog.	1995-01	7604607
Determination of piroximone in human plasma by high-performance liquid chromatography.	1994-10	7846749
Effects of piroximone on the right ventricular function in severe heart failure patients.	1994-05	7930028
Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.	1994-04	8070481
[Continuous monitoring of cardiac output by analysis of the pulse contour].	1994-01	7811153
Postischemic hemodynamic changes after piroximone administration in isolated rabbit heart.	1994	8005173
Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery.	1993-12	8280556
Circulatory effects of the PDE-inhibitors piroximone and enoximone.	1993-10	12959308
Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure.	1993-03	7681513
The influence of clinical intervention on pressure-volume relationships--the conductance (volume) technique.	1992-11	1478213
Acute hemodynamic effects of MDL 19205 in mild congestive heart failure.	1987-02	2436000
Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systems.	1984-01-01	6199611

Sample Use Guides

In Vivo Use Guide

Single dose - 1 mg/kg

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:05 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:05 GMT 2025`
Record UNII	2VSD0380YB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIROXIMONE

Official Name

English

MDL 19,205

Preferred Name

English

PIROXIMONE [USAN]

Common Name

English

piroximone [INN]

Common Name

English

4-Ethyl-5-isonicotinoyl-4-imidazolin-2-one

Systematic Name

English

2H-IMIDAZOL-2-ONE, 4-ETHYL-1,3-DIHYDRO-5-(4-PYRIDINYLCARBONYL)-

Systematic Name

English

PIROXIMONE [MART.]

Common Name

English

MDL-19205

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C744